AstraZeneca Earnings, Sales Rise, Beat Forecasts
By Helena Smolak
AstraZeneca posted increased first-quarter core earnings per share and sales that beat forecasts.
The Anglo-Swedish pharmaceutical giant said Thursday that its core earnings per share increased to $2.06 from $1.92 the prior-year period.
Total revenue rose 19% to $12.68 billion boosted by product sales and continued growth in Alliance Revenue from partnered medicines.
Analysts expected core earnings per share at $1.92 on sales of $11.84 billion, according to a company-compiled consensus.
AstraZeneca reiterated its full-year guidance.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 25, 2024 02:36 ET (06:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks